Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11, 2020 at 8:00 a.m. ET to review operatin...
Sesen Bio, Inc. (SESN) Q4 2019 Earnings Conference Call March 16, 2020 8:00 AM ET Company Participants Erin Clark – Vice President-Corporate Strategy-Investor Relations Thomas Cannell – President and Chief Executive Officer Chad Myskiw – Strategic Planning, C...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Sesen Bio (NASDAQ: SESN ): Q4 GAAP EPS of -$0.32 misses by $0.24 . More news on: Sesen Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion pr...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President and CEO, will host a conference call on Monday, March 16, 2020 at 8:00 a.m. ET to provide a...
Sesen Bio (Nasdaq: SESN ) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and Jason Keyes, chief financial officer of Equill...
Recently, small-cap biotech and pharma tickers have experienced a sharp sell-off, which caused a few watch list tickers pop-up on my scanners for a possible buying opportunity. I was surprised to see Sesen Bio ( SESN ) was one of those discounted tickers considering they are in the process o...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to purchase an aggregate of 85,500 shares of Sesen Bio common stock as an inducem...
2019 saw a major milestone year for Sesen Bio ( SESN ) with Type C CMC Meeting, Type B clinical pre-bla meeting, Type C confirmatory trial meeting, Type B cmc pre-bla meeting, obtaining small business exemption and starting the BLA submission under rolling review. Outside of the large spike in...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...